SI-BONE, Inc.
SIBN
Positions held
Your positionsSIBN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- SI-BONE operates in the growing medical devices sector, focusing on innovative solutions for spinal surgery, which positions it well against competitors in a high-demand market.
- Revenue increased by 7% compared to the prior quarter, reaching $56 million.
- The company's gross margin remains strong at 79.5%, indicating effective cost management despite operating challenges.
- The company has a negative profit margin of -6.85%, reflecting ongoing financial struggles that could deter potential investors.
- In 2023, SI-BONE reported a net income loss of $43.336 million, which highlights significant financial instability.
- The operating margin for the latest quarter was -8.6%, showing that the company is still facing challenges in achieving profitability.
Fundamentals
| Market cap | $845.28M | Enterprise value | $742.13M | Trailing P/E | — | Forward P/E | -57.01 |
| PEG | — | Price / book | 4.62 | Beta | 0.66 | Dividend yield | 0.00% |
| Revenue growth | 15.2% | Earnings growth | — | Gross margin | 79.5% | Operating margin | -8.6% |
| Profit margin | -6.9% | ROE | -8.3% | ROA | -4.6% | Debt / equity | 0.23 |
| Current ratio | 9.15 | Free cash flow | -$861,875 | Analyst recommendation | strong_buy | Mean target | $25.22 |
| 52w high | $21.89 | 52w low | $11.48 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $56.0M | $52.6M | $56.3M | $48.7M | $48.6M |
| Op margin | -8.6% | -9.7% | -4.4% | -11.1% | -14.4% |
| Net income | -$4.1M | -$4.3M | -$1.6M | -$4.6M | -$6.2M |
| Gross margin | 79.5% | 79.8% | 79.0% | 79.8% | 79.8% |
| Gross profit | $44.5M | $41.9M | $44.5M | $38.8M | $38.8M |
| Operating income | -$4.8M | -$5.1M | -$2.5M | -$5.4M | -$7.0M |
- Revenue +7% vs prior quarter ($56M vs $53M).
- Gross margin 79.5% (was 79.8% prior quarter).
- Operating margin expanded to -8.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $201M | $167M | $139M | $106M |
| Op margin | -11.1% | -21.1% | -33.8% | -56.0% |
| Net income | -$18.9M | -$30.9M | -$43.3M | -$61.3M |
| Gross margin | 79.6% | 79.0% | 78.8% | 85.2% |
| Gross profit | $160M | $132M | $109M | $90.7M |
| Operating income | -$22.3M | -$35.2M | -$46.9M | -$59.6M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-31 · SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
2026-08-25 · Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?
2026-08-24 · Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade
2026-08-21 · Si-Bone Insider Sold Shares Worth $337,138, According to a Recent SEC Filing
2026-08-21 · Si-Bone Insider Sold Shares Worth $1,088,201, According to a Recent SEC Filing
2026-08-11 · SI-BONE (SIBN) Q2 2026 Earnings Call Transcript
2026-08-06 · Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?
2026-08-04 · UBS Lifts Price Target on SI-BONE to $25 From $24, Maintains Buy Rating
2026-08-04 · SI-BONE, Inc. Q2 2026 Earnings Call Summary
2026-08-04 · Truist Adjusts Price Target on SI-BONE to $23 From $21, Maintains Buy Rating
2026-08-04 · SI-BONE Inc (SIBN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised ...
Price (daily)
Full chart · RSI · MACD · patterns